Oral administration of Bifidobacterium longum ES1 reduces endometrial inflammation in women with recurrent pregnancy loss

Background Over‐activation of endometrial inflammasome NALP‐3 (Nod‐like receptor family pyrin domain containing 3) can be found in recurrent pregnancy loss (RPL) women probably due to leaky gut and passage into circulation of lipopolysaccharides (LPS). Leaky gut can be caused by exposure to gluten i...

Full description

Saved in:
Bibliographic Details
Published in:American journal of reproductive immunology (1989) 2024-01, Vol.91 (1), p.e13804-n/a
Main Authors: Tersigni, Chiara, Barbaro, Greta, Castellani, Roberta, Onori, Marianna, Granieri, Chiara, Scambia, Giovanni, Di Simone, Nicoletta
Format: Article
Language:English
Subjects:
Bifidobacterium longum
Bifidobacterium longum ES1
Caspase
Celiac disease
Endometrium
Gluten
gut permeability
Haplotypes
Histocompatibility antigen HLA
inflammasome
Inflammasomes
Inflammation
Lipopolysaccharides
NALP‐3
Oral administration
Permeability
Pregnancy
Pyrin protein
recurrent pregnancy loss
Serum levels
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Over‐activation of endometrial inflammasome NALP‐3 (Nod‐like receptor family pyrin domain containing 3) can be found in recurrent pregnancy loss (RPL) women probably due to leaky gut and passage into circulation of lipopolysaccharides (LPS). Leaky gut can be caused by exposure to gluten in RPL women genetically predisposed to celiac disease, positive for Human Leukocyte Antigen (HLA)‐DQ2/DQ8 haplotype. Oral administration of Bifidobacterium longum ES1 (GliadinES®) can inactivate gluten peptides toxicity to epithelial gut cells and improve gut barrier. Methods We investigated by enzyme‐linked immunoassay: (a) serum levels of LPS and zonuline (a marker of leaky gut); (b) LPS, NALP‐3, caspase‐1, interleukine (IL)‐1β and IL‐18 concentration in endometrial fluids, in untreated women with uncomplicated pregnancies (negative HLA‐DQ2/DQ8 haplotype) (n = 22) and in women with unexplained RPL, HLA‐DQ2/DQ8 positive (n = 22), before and after daily oral administration for 3 months of GliadinES®. Results RLP women showed higher serum levels of LPS (p 
ISSN:1046-7408
1600-0897
DOI:10.1111/aji.13804